Skip to main content

Table 1 Demographics of patients and tumors

From: Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas

Case Age (years old) M/F Tumor Bev (cycles) Lesion Location Radiotherapy Bev from RT (month) Reduction Rate Outcome
FLAIR ( %) Gd ( %) Radiological Clinical
Case 1 70 F anaplastic 4 Tumor 1 (non-irradiated) R frontal (cranial)   N/A −71 198 Progression Improved L hemiparesis
Tumor 2 (non-irradiated) R frontal (caudal)   N/A 126 Progression
Tumor 3 R frontal SRT 32Gy 8 −89 Response
Tumor 4 R frontotemporal SRS 23Gy/SRS 20Gy/ SRS 22Gy/ SRT 33Gy 3 7 Stable
Case 2 52 M anaplastic 3 Tumor 5 occipital SRS 14Gy/ SRS 14Gy/ SRT 25.5Gy/BNCT 13 −47 −10 Stable Unchanged dizziness and visual disturbance
Tumor 6 L temporal SRT 27Gy 20 −79 Response
Tumor 7 (non-irradiated) R temporal   N/A −5 Stable
Tumor 8 L tentorial edge SRS 20Gy 2.5 −55 Response
Case 3 76 F atypical 6 Tumor 9 parasagittal SRT 24Gy/ BNCT 8 −29 0 Stable Unchanged L hemiparesis
Case 4 52 M grade I 3 Tumor 10 petroclival GKR 14Gy/RT 30Gy/GKR 14Gy 5.5 −33 −14 Stable Improved R hemiparesis and L ataxia
Case 5 69 F grade I 3 Tumor 11 parasagittal SRS/ SRS 13 −90 −47 Stable Improved gait disturbance
Case 6 46 F anaplastic 6 Tumor 12 frontal base EBRT 60Gy/ BNCT/BNCT 4 −45 −48 Stable Unchanged cognitive dysfunction
Tumor 13 orbit BNCT/BNCT 4 −65 Respose
Tumor 14 infratemporal BNCT/BNCT 4 12 Stable
Tumor 15 frontal convexity EBRT 60Gy/ BNCT/BNCT 4 19 Stable